1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Eisai Expands Dementia Ecosystem Via EcoNaviSta Acquisition

AI-Driven SaaS Platforms

 
• By Lisa Takagi

Move to acquire profitable Tokyo-based venture part of Japanese major's strategy of building a broader ecosystem for dementia detection and care.

Eisai EcoNaviSta
(Shutterstock)

Eisai is planning to acquire the Japanese digital health venture EcoNaviSta through a potential JPY16bn ($107.4m) deal, as the major Japanese pharma firm continues to build out a total care ecosystem “beyond the pill.”

Eisai originally formed an alliance with the Tokyo-based firm in July 2024 to expand its dementia care platform, using EcoNaviSta’s digital technology to monitor daily life rhythms of the elderly...

Along with growth for its commercialized Alzheimer’s disease therapeutic Leqembi (lecanemab) in both the US and Japan, the deal is set to further enhance Eisai’s mild cognitive impairment (MCI) and...

More from Japan

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Multiple Launches Help Lilly’s Japan Growth

 
• By Ian Haydock

Lilly saw solid growth for its business in Japan last year on the back of several new launches and is building its obesity and Alzheimer's portfolios in the country.

Shionogi In $1bn Deal For Japan Tobacco’s Pharma Ops

 
• By Ian Haydock

Mid-sized Japanese pharma firm to acquire tobacco giant’s pharma operations and take private the listed Torii Pharmaceutical business, in bid to build sales reach and strengthen manufacturing.

Japan Market Entry: Consortium’s One-Stop Shop To Support Foreign Entrants

 
• By Lisa Takagi

Japanese CDMO Bushu talks about a consortium designed to provide a broad range of development services to smaller foreign firms looking to bring high-need drugs to the Japanese market.

More from Business

End Is Nigh For 4SC After EMA’s No For Kinselby

 
• By Kevin Grogan

The German biotech has discontinued the oral HDAC inhibitor for cutaneous T-cell lymphoma.

Japan Pharma Sees US Revenues Grow But Policy Impact Still Unclear

 
• By Lisa Takagi

Japanese majors put in generally solid performances in the fiscal year ended 31 March, but overseas revenues and forex effects, rather than the domestic market, provided most of the growth.

Pfizer Scoops 3SBio’s PD-1/VEGF Bispecific In ADC Combo Push

 
• By Dexter Jie Yan

Pfizer is doubling down on partnerships for combination therapies involving its antibody-drug conjugates through a new alliance with China's 3SBio’s for a bispecific antibody, potentially worth up to $6bn.